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Tacalcitol (Curatoderm® 4 jug/g ointment, once daily) was shown to be effec­
tive and safe in the treatment of patients with chronic plaque psoriasis in a 
previous multicentre, placebo-controlled double-blind study. After a 4-week 
medication-free interval, an open-label, prospective study was started with a 
planned minimum duration of 12 weeks. The maximum treatment and observa­
tion period was to last up to 60 weeks. The objective was to investigate the 
efficacy and safety of tacalcitol under the conditions of long-term psoriasis 
management.
Three centres with a total of 90 patients participated in the long-term study 
project. Eighty-one patients had completed the initial double-blind study as 
scheduled and 58 patients entered the long-term phase with tacalcitol ointment. 
Forty-two patients completed at least 12 weeks of treatment. The mean dura­
tion of treatment was 24.8 weeks. In individual cases, the maximum treatment 
period was 62 weeks. After 4 weeks of treatment there was a substantial 
improvement of the sum score (erythema, infiltration, desquamation), which 
was defined as the primary efficacy criterion. This response was maintained 
throughout the study.
Systemic safety variables did not show any clinically relevant influence of 
tacalcitol on calcium metabolism. In particular, serum calcium, creatinine, 
phosphate and nocturnal urine alpha-1-microglobin remained unaffected by 
continuous application of the study medication.
Transient symptoms of local side effects such as burning, itching, pain and 
irritation were reported by only 8 of the 58 patients. These were considered to 
be due to either the psoriasis or tacalcitol. In 6 patients these side effects were 
reported as “moderate” or “mild”. No patient was withdrawn for safety rea­
sons.
In conclusion, this study indicates that tacalcitol ointment is an effective and 
safe treatment for the long-term control of psoriasis vulgaris. These results are 
to be supported by further large-scale studies and in patients with more exten­
sive psoriatic lesions. (Key words: psoriasis, tacalcitol, vitamin D r )
V itamin D3 analogues represent a major innovation in the treatment of psoriasis today [1-4]. During the last5 years, calcipotriol (50 |J,g/g) ointment has become a 
first line therapy for this condition. Calcipotriol treatment is 
generally accepted for long-term management of psoriasis, 
although irritation of the skin has been experienced by 25% 
of the patients and required discontinuation of treatment in 
approximately 6% of the patients [5, 6].
In Japan, tacalcitol (2 jUg/g ointment, twice daily) is the vita­
min D3 analogue which has become the mainstay in the rou­
tine treatment of psoriasis [7-10]. Irritation following tacalci­
tol application has been recorded in less than 1% of the 
patients [7-10]. The clinical efficacy of this formulation pro­
ved to be comparable to twice daily treatment with betame­
thasone valerate 1 mgig ointment [11].
Recently, a European, dose-finding study was carried out to 
assess the optimal concentration and the clinical efficacy of
once daily application of tacalcitol (0.25-16 |xg/g oin- 
ment) [12], Concentrations above 4 jug/g did not enhance the 
antipsoriatic efficacy, whereas lower concentrations were 
significantly less effective. A multicentre, placebo-controlled, 
intraindividual, left-right comparative study was performed 
with 122 patients to investigate the clinical efficacy, side 
effects and tolerability of this dosage regimen in Caucasian 
patients with chronic plaque psoriasis [13]. The application of 
tacalcitol ointment once daily (4 |ig/g for 8 weeks) proved to 
be an effective, safe and well-tolerated antipsoriatic treatment. 
The objective of the present study was to investigate the efficacy 
and safety of tacalcitol ointment 4 |ig/g, applied once daily under 
the conditions of long-term psoriasis management. This study 
was performed in patients who had previously participated in the 
placebo-controlled study and addressed the following questions: 
(1) can the clinical efficacy of tacalcitol ointment, as confirmed 
by the 8-week placebo-controlled study, be maintained during a
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long-term study, (2) does long-term use of this vitamin D, ana­
logue affect systemic safety variables, (3) what is the frequency 
and severity of irritation of the skin during long-term therapy, (4) 
what is the overall assessment of patients and investigators regar­
ding global improvement and usefulness of this treatment?
Study characteristics
General introduction
An open-label, prospective study was performed to investi­
gate the efficacy and safety of tacalcitol (4 pg/g ointment, 
once daily) in the long-term treatment of psoriasis. All 
patients had been previously included in a multicentre, pla­
cebo-controlled, intraindividual, left-right comparative study 
on the efficacy and safety of a short-term treatment with the 
identical tacalcitol formulation [13]. Upon completion of the 
double-blind phase and a medication-free foiiow-up period of 
4 weeks, each patient who was interested and had completed 
the double-blind study could enter the long-term phase.
A total of 146 patients were enrolled in the original double-blind 
study in 15 centres, One hundred and twenty-six patients com­
pleted the double-blind phase of 8 weeks. Twenty patients with­
drew for the following reasons: inadequate efficacy (5 patients), 
prohibited therapy and inadequate efficacy (4), incompatible 
therapy (4), adverse event (1), healing (1) other reasons (5).
The long-term study was performed in three of the 15 centres 
participating in the multicentre study.
Patient selection
Patients with chronic plaque psoriasis were enrolled at 3 aca­
demic centres. All subjects had already fulfilled the inclusion 
and exclusion criteria which were the same as for the 8*week 
placebo-controlled study [13]. In brief, out-patients of either 
sex aged between 15 and 80 years, females of childbearing 
age if they were using adequate contraception and patients 
with normal serum calcium or phosphate were included. Sys­
temic or topical antipsoriatic therapy other than tacalcitol 
treatment within 2 months or 4 weeks respectively prior to 
the start of the study was considered to be an exclusion crite­
rion. Other exclusion criteria were serious diseases, known 
allergy to the study medication, medication interfering with 
the course of psoriasis or systemic calcium metabolism. All 
patients gave informed consent prior to the study.
Study m edication and treatm ent
Tacalcitol ointment was applied once daily by the patients to 
all affected areas except the scalp. The formulation contained 
(4 M-g/g) 1 a,24-dihydroxy-cholecalciferol (tacalcitol) in the
inactive ingredients paraffin oil, diisopropyl adipate and white 
petrolatum ; 100 g tubes were filled with the preparation.
Use of the study medication was restricted to a maximum of 
20 g once daily and a long-term maximum supply of 2,000 g 
per patient.
Patients received a 4-week supply of study medication at the 
start of the long-term period and again at 4-week intervals. 
The patients were permitted to discontinue treatment after a 
minimum duration of 12 weeks. They were regarded as drop­
outs if treatment was stopped before this time. Patients could 
discontinue therapy because of clearing, side effects or if they 
wished to do so. The scheduled maximum treatment and 
observation period was to be 60 weeks.
Efficacy assessm ents
At the start of the open-label, long-term phase (week 0) and 
subsequently every fourth week, clinical efficacy criteria 
were assessed by the investigator. The extent of the psoriatic 
test area was recorded as percentage of the total body surface 
and assessed at baseline and at regular visits. The symptoms 
erythema, infiltration and desquamation were recorded using 
a 5-point scale from 0 = “none” to 4 = “very severe”. In 
addition, at each visit the symptoms erythema and desquama­
tion were compared to their initial condition (week 0). The 
condition was rated as “deteriorated”, “unchanged”, “slightly 
improved”, “moderately improved”, “markedly improved” or 
“cured”. At the end of the study, a global assessment of effi­
cacy was made by the investigator and the patient. An assess­
ment of usefulness was given by the patients at the end of 
treatment on a 10-point analogue scale of 1 = “not useful at 
all” to 10 = “extremely useful”. The sum score (0-12) for 
erythema, infiltration and desquamation was defined as the 
primary criterion of efficacy.
Safety assessm ent -
i
The occurrence of any adverse event was recorded at each 
visit. These events were evaluated for duration, severity 
(slight, moderate or severe) and a possible relationship to 
disease or drugs. In particular, the investigator had to pay 
attention to any signs of irritation, skin rashes, and other local 
reactions and to note their location, extent and severity.
A global assessment of tolerability was given at the end of 
treatment by the investigator and the patient and was rated as 
“very good”, “good”, “moderate” or “insufficient” . The 
patient’s general condition was recorded at the start and at 
each visit during the long-term study. The assessment was 
rated as “very good”, “good”, “moderate” or “insufficient”. A 
clinical laboratory evaluation was performed at baseline and 
at each visit. The haematology comprised determination of 
erythrocytes, platelets, haemoglobin, haematocrit; the blood 
chemistry included serum calcium, inorganic phosphate, crea­
tinine, ASAT, alkaline phosphatase and LDH. Nocturnal 
urine alpha-1-microglobulin was also assessed at one centre.
Statistical analysis
Open label, long-term studies are observational studies prone 
to a high selection bias caused by drop-outs, e.g. statistics are 
biased by self-selection of patients and p-values for tests with 
respect to baseline are also biased by the reduced sample 
size. Thus special analysis methods must be used and results 
have to be interpreted very carefully.
The most important information from such a study includes 
the number (and also type) of patients enrolled and the num­
ber of drop-outs during the study, which should be compiled 
in a life table. An indication of the efficacy and safety of 
drugs is given by specifying the reasons for withdrawal.
The efficacy can be plotted as individual time curves for each 
patient. Statistics for each point in time are not useful as 
these are biased by early selective withdrawal of patients 
with severe symptoms. Thus, only changes from baseline are 
quantified here by means of the Mann-Whitney coefficient, 
which in the case of pre-post values is simply the proportion 
of improved patients relative to all patients showing a chan­
ged condition. Although this takes into account only patients 
with observations at a specified point in time, there may also 
exist a bias caused by patients who have dropped out, so that
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these results must also be interpreted very carefully. The 
Mann-Whitney coefficient can be interpreted as follows:
0.5 = pre-post values equal, 0.64 = moderately superior (rele­
vant), 0.71 = highly superior.
Since laboratory variables that are not related to the clinical 
condition or quality of life may lack a selection bias, statistics 
could be a valid means of interpretation for this type of data.
Results
Patient selection and w ithdraw als
Fifty-eight of 81 patients in 3 centres entered the open-label 
long-term phase. The global efficacy of tacalcitol was asses­
sed at the end of the initial double-blind study for these 
patients as “very good” in 10, “good” in 35, “moderate” in 
10 and “insufficient” in 3 patients. Twenty-three patients did 
not want to enter the new, long-term study.
The mean duration of the long-term phase was 24.8 ± 
17 weeks; the minimum 12-weeks treatment was completed 
by 42 of 58 patients (72.4%).
During this period 16 of 58 patients dropped out for the follo­
wing reasons; early termination due to good response (6), 
inadequate efficacy (6), incompatible therapy (1), non-com­
pliance (2), hospitalization due to other disease (1).
The maximum treatment period was 62 weeks (n = 3). After 
week 12, 5 patients dropped out. The reasons were inade­
quate efficacy (1), prohibited medication (2), other reasons 
(administrative reasons [1], voluntary termination of treat­
ment when the patient was nearly cured [1]).
None of the patients terminated the open-label study because 
of complete clearing. In 5 patients, the test drug was not 
applied as recommended, i.e. continuously throughout the 
study and in 6 patients the last observation was 1 to 4 weeks 
after the end of treatment.
D em ographic and anam nestic data
Fifty-eight patients, 18 women and 40 men, entered the long­
term efficacy and safety study. The average age was 45 years
(range 19 to 78 years). All patients suffered from chronic 
plaque psoriasis. At the beginning of the initial double-blind 
phase, the duration of psoriasis since the first outbreak was 
208 months (median; range 12 to 750 months) and interval 
since the last attack, 10 months (median; range 1 to 439 months). 
The mean time interval from the end of the initial double-blind 
phase to the start of the open-label phase was 4.4 ± 2.6 weeks 
(mean ± SD). The total extent of psoriatic lesions chosen as 
test areas, and calculated as percent of body surface, was 9.9 ±
3.2 (mean ± SD) at the beginning of the initial double-blind 
phase for all patients, 8.3 ± 3.6 (mean ± SD) at the end and 
8.6 ± 3.9 (mean ± SD) at the start of the open-label phase.
The sum score was 8.9 ± 1.5 (mean ± SD) at the beginning 
of the double-blind phase, 4.6 ± 2.1 (mean ± SD) at the end 
and 7.9 ± 2.1 (mean ± SD) at the start of the open-label 
phase. These values show an increase in intensity of symp­
toms in the medication-free interval.
Clinical efficacy
The general impression is that the response obtained in the 
double-blind phase is maintained throughout the open-label 
phase. Apparently, patients with a higher initial value show a 
greater tendency to drop out. The sum score shows a ten­
dency to improve relative to baseline even until week 8 of the 
study, Figure 1 shows the results expressed as a Mann-Whit­
ney coefficient for each point in time. There is a substantial 
improvement immediately (week 4) compared to the start of 
the open-label phase. This was “maintained throughout the 
study. There was a steadily increasing improvement in the 
extension of involved test area from week 4 to week 20.
The global assessment of efficacy by the investigator and the 
patient are summarized in Table I for a total of 58 patients. 
The investigator rated the efficacy as very good in 6 patients 
(10%), as good in 28 (48%), as moderate in 21 (36%) and as 
insufficient only in 3 (5%). Nine (16%) of the patients rated 
the efficacy as very good, 24 (41%) as good, 19 (33%) as 
moderate and 6 (10%) as insufficient. In 84% of the assess­
ments the investigator and the patient were in agreement.
The usefulness of the therapy, as assessed by the patient on a 
10-point analogue scale (0-10), was assessed as 7 (median).
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Figure 1. Involved test areas and 
sum score. The sum score is the 
sum of erythema, induration and 
scaling. The involved test area 
comprises the regions which were 
selected for treatment with tacalci- 
toi
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Table I. Global assessment o f  efficacy by the investigator
and the patient
Efficacy
assessment
Assessment of efficacy by
Investigator (%) Patient (%)
Very good 6 10.34 9 15.52
Good 28 48.28 24 41.38
Moderate 21 36.21 19 32.76
Insufficient 3 5.17 6 10.34
Missing — — — —
Valid No. 58 100.00 58 100.00
Total N  = 58.
Safety
Adverse events were reported by 15 of the 58 patients (26%). 
All extracutaneous adverse events were considered to be 
unrelated to psoriasis or the study medication. In 10 of the 
58 patients, adverse events related to skin were reported. In a 
patient with erysipelas and a patient with urticaria, relation­
ship to the study medication was considered unlikely. In 8 of 
the 10 patients (13.8%) with skin reactions, these reactions 
were considered to be due to either psoriasis or the study 
medication. Three of these 8 patients reported a burning sen­
sation, 3 itching/pain and 2 irritation. These symptoms did 
not increase in severity during long-term application of tacal- 
citol ointment. The cutaneous adverse events were documen­
ted as severe in 2 of 8 patients, as moderate in 4 and as mild 
in 2. Nine of the nineteen adverse events reported occurred 
before study week 12, six from weeks 13 to 24, three from 
weeks 25 to 36 and one in week 44.
Adverse events for 2 different body systems were reported in 
2 patients and for 3 different body systems in 1 patient. None 
of the patients withdrew from the open-1 abel phase as a result 
of adverse events.
The global assessment of tolerability as given by the investi­
gator and the patient is shown in Table II. The tolerability 
was considered good or very good in 98% of the cases by the 
investigator and in 96% by the patient. The patients’ general 
condition was considered good throughout the long-term 
study.
Laboratory investigations did not show any change of clinical 
importance. No patient developed hypercalcaemia.
The Mann-Whitney coefficient for serum calcium, phosphate 
and creatinine showed wide fluctuation, but there was no
indication of negative effects of the study drug and there was 
no systematic negative or positive trend, Non-trivial changes 
after week 20 may also be explained by random fluctuation: 
the number of patients decreased with time.
The plot of individual data versus the study time for calcium, 
phosphate and serum creatinine also show no important 
changes.
The time course of the individual data for alpha-1-microglo­
bulin in urine gives no indication of a time trend. In one 
patient who had suffered from hypertension since 1980, 
values above normal were seen throughout the long-term 
study, except during weeks 12 and 24.
Discussion
The results of the present study suggest that tacalcitol oint­
ment has substantial antipsoriatic efficacy that is maintained 
over the long-term in the majority of patients with psoriasis 
vulgaris.
Eighty-one patients completed the original study as scheduled 
in these 3 centres and 58 patients entered the open-label, 
long-term phase with tacalcitol. A total of 42 patients were 
treated for the planned minimum duration of 12 weeks. 
Twenty-one patients were still in the study after week 24 and 
13 after week 36. The maximum treatment and observation 
period was 62 weeks for 3 patients.
Only 15 patients dropped out because of inadequate efficacy, 
prohibited therapy or other reasons (not included in these 
figures are patients who withdrew of their own accord 
because of good results with the tacalcitol therapy).
The general impression obtained from the change in the 
extension of the involved test areas as a percentage with time 
is that the response achieved in the double-blind phase is 
maintained throughout the open-label phase. Apparently, 
patients with higher baseline values showed a greater ten­
dency to withdraw from the study.
The same pattern was observed for the primary efficacy crite­
rion, the sum score of the three variables: erythema, infiltra­
tion and desquamation. A tendency to improve could even be 
seen until study week 8. The Mann-Whitney coefficient for 
each point in time for the involved test area and sum score 
showed a substantial improvement right at the beginning 
(week 4) compared to baseline (weekO), which was maintai­
ned throughout the study. There was a steady improvement in 
the extension of the involved test area even from week 4 to 
week 20, which might, however, also be explained by the 
drop-out bias.
It can be concluded from the efficacy data that tacalcitol oint­
ment can be applied over a long period of time with good cli­
nical results. The sustained antipsoriatic efficacy without 
signs of intolerance is in line with the efficacy characteristics 
of long-term administration of the vitamin D3 analogue calci- 
potriol [5, 6]. A quantitative comparison of clinical efficacy 
and safety of different vitamin D3 analogues is not yet pos­
sible because of inadequate data.
Adverse events were reported by 15 of the 58 patients (26%). 
All extracutaneous adverse events as well as the erysipelas 
and urticaria in two patients were considered to be unrelated 
to psoriasis or the study m edication. B urning (5%), 
itching/pain (5%) and irritation (3%) were considered to be 
due either to psoriasis or the study medication. These symp­
toms were transient and did not increase in severity or fre­
quency during long-term therapy. None of the patients with­
drew for safety reasons. The irritation rate of tacalcitol in
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Table II. Global assessment o f tolerability by the investigator
and the patient
Assessment of tolerability by
Tolerability
assessment
Investigator (%) Patient (%)
Very good 36 62.07 34 58.62
Good 21 36.21 22 37.93
Moderate 1 1.72 1 1.72
Insufficient — 1 1.72
Missing — — — —
Valid No. 58 100.00 58 100.00
Total AT = 58.
these Caucasian patients is higher compared to the irritation 
reported by Japanese authors. However, the relatively low 
concentration (2 |ig/g twice daily) might be of relevance [7 - 
11], Irritation of the skin has been reported to be a problem 
for other vitamin D, analogues [14, 15], The overall tolerabi­
lity was considered good or very good in 98% of the cases by 
the investigator and m 96% by the patient. In addition, the 
general condition of the patients was considered good throu­
ghout the long-term study.
Based on the safety profile of tacalcitol under long-term 
conditions, this new treatment can be regarded as a safe 
approach to psoriasis management. There proved to be no 
influence on the general condition of the patients. Haemato­
logy and blood chemistry revealed no clinically significant 
changes. In particular, serum calcium, phosphate and creati­
nine remained within the normal range. Recently, nocturnal 
urine alpha-1-microglobulin (protein HC) has proved to be a 
valuable marker for tubular dysfunction [16], which is an 
early sign of calcium deposition in the parenchyme of the 
kidney. This marker remained unaffected as well.
The usefulness of tacalcitol ointment was judged to be 7 on a 
10 point scale. This implies that tacalcitol is not the panacea 
of psoriasis treatment but rather represents a well-accepted, 
once daily treatment with a medium antipsoriatic efficacy that 
is maintained long-term. The excellent local tolerability sug­
gests that tacalcitol therapy might also be indicated for the 
treatment of facial and flexural psoriasis. Further studies are 
required to compare the clinical efficacy and safety profile of 
tacalcitol with those of other vitamin D3 analogues and to 
study the long-term efficacy and safety in larger patient 
populations, and with more extensive psoriasis. M
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